Cantargia partners with BioInvent International for CAN10 manufacturing contract
Sweden-based biopharmaceutical company Cantargia has entered a significant partnership with BioInvent International to advance the manufacturing of CAN10, a monoclonal antibody currently in preclinical development for the treatment of systemic sclerosis and myocarditis. This agreement marks a strategic step forward in Cantargia’s efforts to bring CAN10, which targets the inflammatory cytokine IL-1RAP, into clinical trials.
BioInvent to support production of CAN10 for clinical trials
Under the terms of the manufacturing agreement, BioInvent will play a pivotal role in the production of CAN10. This fully humanized monoclonal antibody is designed to target IL-1RAP, a key player in the signaling of several inflammatory cytokines, including IL-1, IL-33, and IL-36. These cytokines are implicated in various inflammatory diseases, and CAN10’s ability to inhibit their signaling provides the therapeutic potential for treating conditions like systemic sclerosis and myocarditis, both of which have significant unmet medical needs.
The manufacturing contract, valued at up to SEK 30 million, will see BioInvent take responsibility for the entire process development. This includes scale-up, the provision of material for toxicological studies, and the creation of clinical-grade material in a 1000L scale for use in upcoming Phase 1 and Phase 2 clinical trials. The partnership is expected to accelerate the timeline for CAN10’s clinical development, with the majority of the manufacturing set to be completed by the end of 2024.
Strategic collaboration to accelerate clinical trials
Cantargia’s CEO, Göran Forsberg, expressed enthusiasm about the collaboration with BioInvent, highlighting the importance of BioInvent’s deep expertise in antibody development. Forsberg emphasized that the advanced manufacturing capabilities and recent investments made by BioInvent will facilitate efficient and timely production of CAN10, enabling the company to move forward into clinical trials as soon as possible.
The partnership is also crucial for Cantargia’s long-term strategy, as it focuses on developing antibody-based therapeutics for a range of inflammatory diseases and cancers. By leveraging BioInvent’s established manufacturing process, Cantargia can reduce the complexity and risks associated with scaling up production, which is often a bottleneck in the biopharmaceutical industry.
BioInvent’s growing reputation in antibody manufacturing
For BioInvent, this collaboration underscores the company’s growing expertise and reputation in the field of antibody manufacturing. Martin Welschof, CEO of BioInvent, noted that the partnership with Cantargia is a testament to the company’s proven capabilities in manufacturing high-quality, state-of-the-art antibodies. BioInvent’s ability to meet the complex demands of large-scale production for clinical trials positions it as a key player in the biopharmaceutical manufacturing space.
This partnership further expands BioInvent’s portfolio of manufacturing customers, enhancing its standing in the competitive landscape of antibody therapeutics. As more companies look to advance their antibody-based treatments into clinical trials, BioInvent’s role in supporting this shift is likely to grow.
Future potential for CAN10 in inflammatory disease treatment
The preclinical development of CAN10 is a significant step in addressing chronic inflammatory diseases. With its unique mechanism of action targeting IL-1RAP and its ability to modulate key cytokines involved in inflammation, CAN10 holds promise for treating a range of diseases where inflammation plays a critical role. If successful in clinical trials, CAN10 could offer a novel therapeutic option for patients suffering from conditions like systemic sclerosis and myocarditis, both of which currently lack effective treatments.
Cantargia’s collaboration with BioInvent is poised to drive the development of this innovative therapy, and the rapid progress towards clinical trials reflects both companies’ commitment to improving patient outcomes in the realm of inflammatory diseases.
A promising step for CAN10 and Cantargia’s future
The contract between Cantargia and BioInvent represents a strategic and critical step in the development of CAN10. With BioInvent’s manufacturing expertise and Cantargia’s innovative therapeutic focus, this partnership sets the stage for potential breakthroughs in treating systemic sclerosis, myocarditis, and other inflammatory diseases. As the manufacturing process progresses towards clinical-grade production, the industry will be watching closely to see how CAN10 performs in upcoming clinical trials.
This collaboration not only showcases the strength of Swedish biopharmaceutical companies in advancing antibody-based therapeutics but also underscores the growing importance of specialized contract manufacturing partnerships in the successful development of novel treatments.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.